Coherus Biosciences has made a number of distribution deals to bring its Humira (adalimumab) biosimilar Yusimry (adalimumab-aqvh) to patients, as a second pharmacy benefit manager steps up to offer the drug to its members through Mark Cuban Cost Plus Drug Company. The biosimilar developer has also struck a national distribution agreement for Yusimry through specialty pharmacy Superior Biologics.
Coherus’s Low List Price Adalimumab Stacking Up PBM And Pharmacy Partnerships
Analysts Still Confident In Humira’s Market Share Despite Increasing Competition
Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader.
More from Biosimilars
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
More from Products
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.